Anticipation for ISTH 2025 Congress in Washington, D.C.
The International Society on Thrombosis and Haemostasis (ISTH) is gearing up for an exciting gathering that promises to bring together nearly 5,000 participants from around the globe at the ISTH 2025 Congress. This exceptional event, taking place at the Walter E. Washington Convention Center, will serve as a platform for leading experts in the thrombosis and hemostasis community to share their insights and innovations.
Highlighting Late-Breakthrough Abstracts
A significant draw for attendees will be the presentation of late-breakthrough abstracts, showcasing new findings from noteworthy clinical trials and research studies. This segment serves as an opportunity for participants to obtain first-hand knowledge of groundbreaking discoveries that could impact the field.
Event Details and Sessions
The late-breakthrough abstracts will be presented during a dedicated session on Sunday, June 22, from 9:30 to 10:45 a.m. in Ballroom A-C. Attendees can expect to engage with studies that cover a range of topics:
- Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Acute Venous Thromboembolism by Lana Castellucci, M.D., from the Ottawa Hospital Research Institute, University of Ottawa.
- Phase 3 Study of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia A by Robert Sidonio, M.D., from Emory University School of Medicine.
- Promoting the thrombosis-induced Alox15 pathway for the treatment of sepsis-induced lung injury by Colin Evans, Ph.D., from the University of South Carolina School of Medicine.
- VELORA Pioneer: first-in-human safety and PK/PD study of HMB-002 in Type 1 Von Willebrand disease by Priyanka Raheja, M.D., from The Royal London Hospital Haemophilia Centre Barts Health NHS Trust.
- Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura by Paul Coppo, M.D., Ph.D., from the Department of Hematology and National Reference Center for Thrombotic Microangiopathies Hôpital Sai.
Details regarding the late-breakthrough abstracts are currently under embargo until the scheduled presentation time.
Welcoming Statements from Organizers
Dr. Guy Young, Chair of the ISTH 2025 Annual Congress Planning Committee, expressed his excitement leading up to the event. "I’m thrilled that the ISTH 2025 Congress will soon convene in Washington, D.C. with some of the brightest minds in our field. Attendees will enjoy a world-class scientific program that fosters collaboration and sparks innovation in thrombosis and hemostasis science," he stated.
Engagement and Options for Professionals
In addition to the scientific sessions, the ISTH 2025 Congress will host an extensive industry exhibition. Here, attendees will have the chance to explore the latest advancements in diagnostics and therapeutics, further enhancing their professional knowledge and capabilities in patient care.
Media representatives are encouraged to register for complimentary press access. For further details on registration, please visit the ISTH 2025 Virtual Press Room.
About the ISTH
Founded in 1969, the ISTH is a premier international organization committed to enhancing the understanding, prevention, diagnosis, and treatment of thrombosis and hemostasis-related conditions. This robust community includes over 7,000 professionals—clinicians, researchers, and educators—from more than 120 countries. The ISTH plays a pivotal role in advancing scientific knowledge in this area through its educational initiatives, research activities, and international meetings.
For additional information about the organization and its dedication to advancing care and research, industry professionals can learn more at the ISTH official site.
Frequently Asked Questions
What is the ISTH 2025 Congress?
The ISTH 2025 Congress is an upcoming event that brings together experts in thrombosis and hemostasis to share insights and findings.
When will the Congress take place?
The Congress is scheduled for June 21-25, 2025.
What are late-breakthrough abstracts?
Late-breakthrough abstracts are presentations showcasing new findings from significant clinical trials and research studies, offered during the Congress.
Who can attend the ISTH 2025 Congress?
The congress is open to anyone in the global thrombosis and hemostasis community, including researchers, healthcare professionals, and industry representatives.
How can attendees register for the event?
Attendees can register for the event through the ISTH official website, with options for press registration available as well.
